Pharmaron Beijing Co., Ltd. released a new announcement on 30 March 2026 proposing a final ordinary cash dividend of RMB2 for every 10 shares (equivalent to RMB0.20 per share) for the financial year ended 31 December 2025.

The distribution remains subject to approval at the forthcoming annual general meeting. If endorsed, the company expects to complete the dividend payment by the end of August 2026.

Key timetable details—including ex-dividend date, record date, book-closure period, shareholders’ approval date, and applicable exchange rate for Hong Kong-traded shares—will be disclosed in subsequent updates. Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong) has been appointed as the share registrar.

The announcement did not specify any withholding-tax arrangement or list any outstanding warrants or convertible securities.

Pharmaron’s board currently comprises nine directors: executive directors Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei; employee-representative director Mr. Li Shing Chung Gilbert; non-executive directors Mr. Li Jiaqing and Ms. Wan Xuan; and independent non-executive directors Ms. Li Lihua, Prof. Tsang King Fung and Mr. Yu Jian.